Free Newsletter
Agent prevents tumors from developing in bones
Researchers at UT's M.D. Anderson Cancer Center have used a "Trojan Horse" to prevent bone tumors from developing in mice. The agent--VEGF121/rGel--prevented cells from eating away at the bone of half the mice involved in the study to make room for tumors to grow. Their research specifically dealt with prostate cancer cells, but has implications for preventing metastasis for breast, multiple myeloma, lung and renal cell cancers.
"Many tumors invade bone in the same way, so these findings suggest it may be possible to shut down this process regardless of the tumor type," says the study's lead author, Michael G. Rosenblum, Ph.D., professor in the Department of Experimental Therapeutics. "If that could be done--and we are a long way from determining if it is possible--we may be able to offer the first treatment that specifically targets bone metastasis."
- see the release on the new cancer research
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




